But tolebrutinib showed something novel at ECTRIMS. In the phase III HERCULES trial, tolebrutinib slowed confirmed disability ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

Brain volume loss is a key marker of degeneration in multiple sclerosis, correlated with future disability progression. Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod ...

Cardiac complications like arrhythmias, heart failure, and myocardial infarction significantly impact mortality rates in patients with comorbidities. The interaction between cardiac issues and ...

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

Phase 3 trial results Tolebrutinib (Sanofi) Bruton tyrosine kinase inhibitor Treatment of non-relapsing secondary progressive multiple sclerosis. Phase 3 trial results Depemokimab (GSK) Ultra-long ...

Findings showed the study met its primary endpoint demonstrating a reduction in disability accumulation with tolebrutinib compared with placebo. Tolebrutinib was found to delay disability progression ...

But three — tolebrutinib, fenebrutinib, and remibrutinib — are now in late-stage trials. The race is on as several drugmakers get closer to the finish line in developing the first Bruton tyrosine ...

A positive result for Bruton’s tyrosine kinase inhibitor after the drug had been put on partial clinical hold due to concerns about liver toxicity.

The recent results of tolebrutinib in non-active secondary progressive MS presented at the ECTRIMS 2024 conference, reinforce the scientific hypothesis that targeting microglia in nSPMS is a valid ...

Finally, Dr Coyle examines the efficacy of the Bruton tyrosine kinase (BTK) inhibitor tolebrutinib, as evidenced by the HERCULES trial and the two GEMINI trials. In HERCULES, the BTK inhibitor ...

Phase 3 of Sanofi’s HERCULES study shows that tolebrutinib, the company’s investigational treatment for SPMS, delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% ...